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Prevention of mother-to-child HIV transmission (PMTCT) strategies include combined
short-course antiretrovirals during pregnancy (Option A), triple-drug antiretroviral treament
(ART) during pregnancy and breastfeeding (Option B), or lifelong ART (Option B+). The
WHO also recommends ART for HIV treatment and prevention of sexual transmission of
HIV. The impact of PMTCT strategies on prevention of sexual HIV transmission of HIV is
not known. We estimated the population-level impact of PMTCT interventions on heterosex-
ual HIV transmission in southwestern Uganda and KwaZulu-Natal, South Africa, two
regions with different HIV prevalence and fertility rates.
Materials and Methods
We constructed and validated dynamic, stochastic, network-based HIV transmission mod-
els for each region. PMTCT Options A, B, and B+ were simulated over ten years under
three scenarios: 1) current ART and PMTCT coverage, 2) current ART and high PMTCT
coverage, and 3) high ART and PMTCT coverage. We compared adult HIV incidence after
ten years of each intervention to Option A (and current ART) at current coverage.
Results
At current coverage, Options B and B+ reduced heterosexual HIV incidence by about 5%
and 15%, respectively, in both countries. With current ART and high PMTCT coverage,
Option B+ reduced HIV incidence by 35% in Uganda and 19% in South Africa, while Option
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B had smaller, but meaningful, reductions. The greatest reductions in HIV incidence were
achieved with high ART and PMTCT coverage. In this scenario, all PMTCT strategies
yielded similar results.
Discussion
Implementation of Options B/B+ reduces adult HIV incidence, with greater effect (relative to
Option A at current levels) in Uganda than South Africa. These results are likely driven by
Uganda’s higher fertility rates.
Introduction
The 2013 World Health Organization (WHO) guidelines to prevent mother-to-child transmis-
sion (PMTCT) of HIV recommend triple-drug antiretroviral treatment (ART) for all pregnant
women for the duration of pregnancy and breastfeeding (Option B) or for life (Option B+) [1].
Previous guidelines recommended Option B or Option A, a short-course regimen of zidovu-
dine (AZT) during pregnancy, single dose nevaripine (NVP) during labor, AZT plus lamivu-
dine for seven days postpartum, and infant NVP during breastfeeding [2]. In all cases,
pregnant women eligible for combination antiretroviral therapy (ART) by national treatment
guidelines should receive lifelong ART for their own health [1,2].
Option B provides significant clinical and programmatic advantages over Option A because
it utilizes a single regimen for both treatment and PMTCT [1]. Option B+ has the potential to
simplify Option B by keeping pregnant women on treatment for life, rather than requiring
repeated initiation and cessation of treatment for multiple pregnancies [3]. Although Option B
+ may be more effective than Option B for PMTCT, the extent to which this is so will depend
on factors such as fertility rates, breastfeeding duration, and retention on treatment, and cur-
rent evidence remains inconclusive [1]. ART reduces the risk of sexual HIV transmission
through viral suppression [4], hence, Options B and B+ also have the potential to decrease HIV
incidence due to sexual transmission.
Prior work has shown that pregnancy is associated with increased genital HIV shedding [5–
8], and an increased risk of sexual HIV transmission [aHR = 2.47; 95% CI 1.26,4.85] within
HIV serodiscordant partnerships [9]. PMTCT interventions target women during this period
of increased transmissibility, and hence may have a disproportionate impact on HIV incidence.
Additionally, pregnant women are a target group that is already involved in care, and there is
room to scale up coverage of PMTCT to expand the possible benefits of the treatment-as-pre-
vention potential of PMTCT. However, little is known about the population-level effects of
Options B or B+; a full assessment requires a detailed analysis of impact on sexual transmission
of HIV. Two unanswered questions are: How do Options B and B+ impact adult HIV inci-
dence, at different levels of coverage? Is there a substantial reduction in adult HIV incidence
under Option B+, given that it may be simpler but costlier to implement? Previously, an ethno-
graphic study in Tanzania showed that women preferred Option B due to its shorter treatment
duration [10], and a clinical trial studying benefits of Option B+ is in progress in Malawi [11].
Two modeling studies on the benefits of WHO PMTCT guidelines focused exclusively on out-
comes related to mother-to-child transmission [12,13], and one other considered sexual trans-
missions in addition to MTCT [14]. Option B+ was found to have the largest improvement for
maternal and infant life expectancy in Zimbabwe [13], and was also the most cost-effective in a
comparative analysis of Kenya, Zimbabwe, South Africa and Vietnam [14]. However, none of
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the prior modeling studies explicitly compared different PMTCT regimens at different cover-
age levels, or used partnership-level data and the sexual networks through which HIV infec-
tions transmit. While Gopalappa et al. [14] did consider adult HIV infections, they relied on an
estimate of the number of infections averted per person-year on ART rather than modeling
sexual transmission of HIV directly.
Thus, while some work on the effects of mother-to-child transmission has been undertaken,
very little is known about the impact of PMTCT on adult HIV incidence, in particular the
amount by which different PMTCT regimens may reduce horizontal transmission, and how
these reductions vary with PMTCT coverage. We analyze the impact of PMTCT regimens
exclusively on adult HIV incidence, and consider the impact on incidence at different coverage
levels, while focusing explicitly on fertility rates as a determinant of this impact.
We hypothesized that Option B+ substantially decreases HIV incidence in adults due to sex-
ual transmission compared to Option B, which decreases HIV incidence more than Option A,
and that the magnitude of this decrease correlates with fertility rates. While it seems likely that
Options B and B+ will each have a greater effect on HIV incidence, we have little intuition on
how much greater the effect will be, especially when coverage levels and fertility rates are incor-
porated in the model. These hypotheses were tested in two sub-Saharan African regions: south-
western (SW) Uganda, with moderate HIV prevalence (about 10% [15]) and a high fertility
rate (total fertility rate of 5.9 per woman [16]), and KwaZulu-Natal (KZN), South Africa, with
a high HIV prevalence (about 25% [17]) and lower fertility rate (total fertility rate of 2.2 per
woman [16]). Mathematical models were used to estimate the impact of Options A, B, and B
+ on HIV incidence due to heterosexual transmission at different coverage levels in each set-
tings. In scenario analyses, we assessed the impact of fertility rates on our results, and their sen-
sitivity to ART initiation at a higher CD4 count.
Materials and Methods
Dynamic, stochastic, network-based models simulated HIV transmission among persons aged
18–55 years in SW Uganda and KZN, and were parameterized using demographic, biological,
behavioral, and treatment data from those settings. Methods are summarized here and pro-
vided in full detail in the Supplementary Appendix. The models were derived from the expo-
nential-family random graph modeling (ERGM) framework, and programmed using the
Statnet [18] packages in the R programming language. In all models, one simulated timestep
was defined to be 14 days.
Baseline HIV epidemics were simulated to capture existing epidemic features in the two
countries, including ART coverage levels and Option A for PMTCT. (For the rest of this paper,
the term “ART” denotes combination antiretroviral treatment that is initiated not as part of a
PMTCT regimen.) The baseline simulation ran for 40 years in SW Uganda and 30 years in
KZN to achieve approximately stable HIV incidence and prevalence (Fig 1). These baseline
models were created to capture the late-stage HIV epidemics in Uganda [19] and South Africa
[20], and the current rates of new infections in both countries. While both countries show signs
of declining incidence, it is important to remember that both ART and PMTCT have been
scaled up in the recent past; calibration of our baseline models did not include ART or PMTCT
scale-up, and we did not aim to model these trends. Our goal was to obtain reasonable epidemic
outcomes (incidence [21,22] and prevalence [15,17]) that are consistent with estimates from
other published studies, to serve as the starting point for modeling interventions. The baseline
models should not be interpreted as a reconstruction of the historical trajectory of the epidemic.
After the baseline phase, PMTCT interventions Options A, B, and B+ were simulated over
ten years. Our baseline and intervention simulations only included heterosexual transmission;
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we did not include the impact of treatment on mother-to-child transmission (MTCT) in our
models. Our primary question was to consider changes in heterosexual incidence rates over 10
years, and our modeled population included individuals between 18 and 55 years of age.
Because the interventions were only modeled over 10 years, any children born during this time
would not age enough to join the sexually active model population. Therefore, including trans-
mission to newborn infants would not directly impact outcomes. However, we did include
HIV prevalence at entry consistent with data for infection rates among 18-year old men and
women (on average, about 3% for both Uganda [23] and South Africa [17]).
In Option A, HIV-infected pregnant women with CD4>350 cells/μl received AZT from the
first antenatal visit until delivery [2]. In Option B, HIV-infected pregnant women with
CD4>350 cells/μl received triple-drug PMTCT from the first antenatal visit until the conclu-
sion of breast-feeding at 12 months postpartum [2]. In Options A and B, pregnant women
with CD4350 cells/μl initiated lifelong ART. In Option B+, all HIV-infected pregnant
women initiated lifelong ART regardless of CD4 count [1].
Each PMTCT intervention was simulated at three population coverage levels: “Current
ART and PMTCT”, “High PMTCT” (with ART at Current levels), and “High ART and
PMTCT” (Table 1). Current coverage included initiation at 22 weeks gestation, with 57% [23]
of HIV-infected pregnant women accessing either PMTCT or ART (“uptake”) in Uganda and
89% [24] in South Africa. We assumed 75% adherence to PMTCT in this population [25]. Cov-
erage was calculated as the product of uptake and adherence: 43% in SW Uganda and 67% in
KZN. This method makes the conservative assumption that non-adherent individuals receive
no benefit of treatment and have the same outcomes as untreated individuals.
Current coverage assumed ART initiation for males and non-pregnant females at a CD4
count of 131 cells/μl [26] at 48% uptake in Uganda, and 100 cells/μl [27] at 53% uptake in
Fig 1. Prevalence plots to produce baseline epidemics in Uganda and South Africa.
doi:10.1371/journal.pone.0134271.g001
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South Africa. Adherence was estimated by the proportion of individuals on treatment who
were virally suppressed: 88% in SW Uganda and 85% in KZN [28]. As with PMTCT, ART cov-
erage was the product of uptake and adherence: 43% in Uganda and 45% in South Africa.
These coverage levels determine the proportion of HIV-infected individuals who will ever
access ART in the baseline model.
We defined High PMTCT coverage as PMTCT initiation at 14 weeks gestation [1], with
90% uptake in both regions. Adherence remained at 75%. In KZN, the main change in this sce-
nario was earlier initiation of PMTCT, because uptake was already close to 90%. In Uganda,
the High PMTCT scenario included substantive changes to uptake and timing of PMTCT
initiation.
Under High ART and PMTCT coverage, the High PMTCT settings were retained and ART
uptake for men and non-pregnant women was set to 90% in both regions, with initiation at
CD4350 cells/μl). ART adherence levels did not change [28]. All interventions are rolled out
in the first year of the intervention at the specified levels.
Data
Our primary data source was a prospective study of home HIV testing and counseling (HTC)
to improve testing and linkage to care [28]. Home HTC was offered to consenting adults (18
years) in defined geographic regions in the Mbarara district of SW Uganda, and Vulindlela dis-
trict of KZN, South Africa. A total of 2,121 individuals in Uganda and 1,272 individuals in
South Africa were tested. The study also included a pre-intervention community survey
(n = 232 in SW Uganda and n = 268 in KZN) [28]. The study provided model parameters for
sexual network characteristics, including the momentary (cross-sectional) distribution of the
number of partnerships, start and end dates of the last three partnerships, mixing by age, and
ART uptake and adherence. The sexual network data from the empirical study represented lon-
ger-term primary and casual partnerships. Due to limitations of this data, we did not model
short-term or once-off sexual partnerships. Published sources were used to parameterize addi-
tional components of our models, as described in the Supplementary Appendix.
Components of Simulation
Each country was populated with 5,000 individuals at the start of the simulations. At each time-
step, our simulations contained the following steps, with input parameters described in
Table 2:
Table 1. Coverage levels for the three scenarios that wemodeled. Parameter estimates for Southwestersn Uganda (SWUganda) and KwaZulu-Natal
(KZN) are separated by commas.
Coverage Level
Current High PMTCT High ART and PMTCT
PMTCT
PMTCT initiation (weeks) 22, 22 14 [62], 14 [62] Same as High PMTCT
PMTCT uptake (%) 57 [23], 53 [24] 90, 90 [assumption] Same as High PMTCT
ART
CD4 count at ART initiation (cells/μl) 131 [26], 100 [63] 131 [26], 100 [26] 350, 350 [assumption]
ART uptake (%) 48 [64], 53 [64] 48 [64], 53 [64] 90, 90 [assumption]
Proportion of those on ART who are virally suppressed (%) 88 [64], 85 [64] 88 [64], 85 [64] Same as Current
doi:10.1371/journal.pone.0134271.t001
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Table 2. Input parameters for our models.
SW Uganda KZN References
Behavior
Mean partnership duration (years) 11.8 8.8* [28]
Mean number of partnerships (per
person)
0.8 1.0 [28]
Frequency of unprotected sex (per
partnership per week)
2.4 2.4 [49]
Distribution of number of partnerships Men: 0 (35%), 1 (52)%, 2 (10%), 3 (3);
Women: 0 (22%), 1 (76%), 2 (2%)
Men: 0 (14%), 1 (66%), 2 (11%), 3 (5%), 4 (2.5%), 5
(2.5%); Women: 0 (24%), 1 (73%), 2 (2%),
[28]
Age mixing Mixing matrix in appendix Mixing matrix in appendix [28]
Biology





Level of: Peak viremia Viral set point




Lifespan of untreated individuals 3301 days [67]
Infection Transmission
Per act (chronic stage) Specific to viral load (details in appendix) [48]
Mulitipliers for:
Acute stage 4.98 [49]
Late stage 3.49 [49]
HSV infection in either partner 2.14*population prevalence (68%) [48]
Pregnancy of HIV-infected 1.7 [69]
Pregnancy of HIV-uninfected 2.5 [69]
Circumcision of uninfected man 0.53 [48]
Combination ART
Change in CD4 CD4 count recovers by 15 cells/μl every month until pre-infection level [40] or for 3 years [38],
whichever is first
Inline
Changes in viral load Declines to 50 copies/ml in 4 months [46]
PMTCT
CD4 count during treatment Option A: Increases 50 cells/μl from initiation to delivery; Option B: Increases 15 cells/μl every
month until pre-infection level; Option B+: Increases 15 cells/μl every month until pre-infection
level or 3 years, whichever is first
[40]
CD4 count upon cessation of
treatment
Option A: Declines to pre-treatment levels in 1 month [40]; Option B: Declines to pre-treatment
levels in 2 months; Option B+[45]: NA
Inline
Viral load during treatment Option A: Declines 1.1 log from initiation to delivery [40]; Option B: Declines to 50 copies/ml in 4
months [45]; Option B+: Same as Option B [45]
Inline
Viral load upon cessation of treatment Option A: Increases to pre-treatment levels in 1 month [41]; Option B: Increases to pre-treatment
levels in 2 months; Option B+: NA
Inline
Pregnancy
Age-specific fertility rates (per 1000
person years)***
See Table S4 in S1 Text [35]
Eligibility for pregnancy Age between 15 and 49 years 15 months since onset of last pregnancy
HIV infection and pregnancy HIV-infected women have a 47% lower age-specificfertility rate [36]
* We increased the mean partnership duration by approximately 3 years to match incidence data.
** We decreased the proportion of women with 0 partners and increased the proportion of women with 1 partner by 20% to balance the total number of
partnerships between men and women.
*** Annual fertility rates in UN Data increased by 15% to match empirical data on proportion of 18–49 year old pregnant women at any cross-section
doi:10.1371/journal.pone.0134271.t002
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1. Mortality: The model included age-specific mortality for uninfected individuals [29,30] and
CD4-dependent mortality [31,32] for infected individuals. Additionally, individuals exited
the model at age 55 when they were no longer a part of the population of interest.
2. Entry into population: Individuals entered the population at age 18, with entry rates selected
to achieve a net national population growth rates of 3–4% per year in Uganda [33] and
1–2% per year in South Africa [34].
3. Formation and dissolution of partnerships: Only heterosexual partnerships were modeled.
The process of partnership formation depended on the partners’ ages and the number of
existing partnerships for each individual. The mean number of partnerships and momen-
tary distribution of partnership numbers were parameterized from the Home HTC study
[28]. All partnerships had an equal probability of dissolution per time step (i.e. lengths of
partnerships were geometrically distributed), estimated using the mean duration of extant
(ongoing) partnerships (Table 2).
4. Pregnancy: Women aged 18–49 years whose last pregnancy started15 months ago were
eligible to become pregnant. Pregnancy onset was modeled as a Bernoulli event with proba-
bilities estimated from country- and age-specific fertility rates [35]. HIV-infected women
were 47% less likely to become pregnant than HIV-uninfected women [36].
5. Update of CD4 count: All adults had a sex-specific uniform CD4 count until seroconversion
(518 cells/μl in men and 570 cells/μl in women [37]). After seroconversion, CD4 counts of
untreated individuals declined as a function of age and sex [37]. For individuals initiating
ART or Option B+, CD4 counts increased for three years after initiation [38], or until they
returned to pre-infection levels [39], whichever occurred first. Under Options A or B, CD4
counts increased for the duration of treatment [40], and declined to pre-treatment levels in
one [41] or two [42] months after cessation of treatment, respectively.
6. Update of viral load: Viral load trajectories were modeled as curves [43,44] defined by: time
to peak viremia; duration of acute, chronic, and late-stage infection; magnitude of peak vire-
mia; set-point viral load; and maximum late-stage viral load. We assumed each part of this
curve to be linear. For women receiving Option A, viral load declined by 1.1 log (base 10)
copies/mL between treatment initiation and delivery [40]. For individuals receiving ART, or
Options B or B+, viral load declined to 50 copies/mL over 4 months [45,46]. Viral load
returned to pre-treatment levels in one and two months upon cessation of Options A [41]
and B [47], respectively.
7. HIV transmission: The probability of HIV transmission per sex act in serodiscordant cou-
ples was a function of viral load of the infected partner [48], circumcision status of the unin-
fected male partner, and pregnancy status of the female partner, and was adjusted for
population prevalence of herpes simplex virus type 2 (HSV-2). The probabilities of trans-
mission per timestep were calculated using the binomial formula, assuming a constant fre-
quency of unprotected heterosexual intercourse [49].
To obtain reasonable HIV prevalence and incidence as outputs in the model, in South
Africa, we increased the mean partnership duration by approximately 3 years to match inci-
dence data. In Uganda, to balance the number of partners reported by men and women, we
decreased the proportion of women with 0 partners and increased the proportion of women
with 1 partner by 20%. In both countries, annual fertility rates in UN Data were increased by
15% to match empirical data on proportion of 18–49 year old pregnant women at any cross-
section.
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Outcomes
The primary outcome was adult HIV incidence in the tenth year of implementation (not
cumulative over the ten years), averaged over 10 model simulations. We computed 95% confi-
dence intervals using a theoretical t-distribution, defined as X  tdf ¼ ðn1Þ; 0:975 sffiffinp , where X is
the outcome of interest, n is the number of simulation runs, and σ is the standard deviation.
These confidence intervals only capture variation across simulations, not variation due to
changing parameter values.
A secondary outcome was the proportion of all HIV-infected individuals (including treated
and untreated individuals in the denominator) who were virally suppressed (viral load100
copies/mL) for all interventions and coverage levels (see Supplementary Appendix). To explore
the relationship between PMTCT coverage, viral suppression, and HIV incidence, we calcu-
lated incidence rates and the proportion virally suppressed after ten years for Option B+ at
Current ART coverage and PMTCT coverage of 20%, 40%, 60%, and 80%, with initation at 14
weeks gestation.
Scenario Analyses
To understand the relative impact of age-specific fertility rates (ASFRs) as a determinant of the
impact of PMTCT on HIV incidence rates, the two countries’ ASFRs were switched and the
change in incidence between Options A at Current coverage and Option B+ at High PMTCT
(and Current ART) coverage was estimated.
In January 2014, Ugandan HIV treatment guidelines extended ART to all HIV-infected
individuals with CD4500 cells/μl [50]. South Africa started to implement the same policy in
January 2015 [51]. We estimated the effect of PMTCT interventions with this revised ART eli-
gibility criterion for each country. We revised the mean CD4 count at initiation to 174 cells/μl
in SW Uganda, and 168 cells/μl in KZN. ART coverage for SW Uganda did not change, and
was revised to 51% of all HIV-infected individuals for KZN (see Supplementary Appendix for
details). We estimated incidence rates for each region (with their original ASFRs) under Option
A at Current coverage, and Option B+ at Current ART and High PMTCT coverage.
Results
For SW Uganda, the baseline model resulted in 10% HIV prevalence and an incidence of 1.00
per 100 person years (py) [95% CI: 0.94, 1.05]; these estimates compared well with observed
data (Fig 1) [15,21]. Similarly, for KZN, model output for current HIV prevalence (25%) and
incidence (2.52 per 100 py; [95% CI: 2.31, 2.73]) were consistent with observed estimates
[17,22]. We compared incidence rates under different PMTCT interventions at different cover-
age levels to baseline estimates, where baseline reflects a continuation of Option A at Current
coverage levels for 10 years. All mean incidence rates apply to the tenth year of intervention in
units of new infections per 100 py, with the 95% CI in brackets.
For SW Uganda, Options B and B+ at Current coverage produced mean incidence rates of
0.95 [0.89, 1.02] and 0.85 [0.81, 0.88] (Fig 2), corresponding to declines of 5% and 15% from
baseline, respectively. With Options A, B, and B+, the High PMTCT intervention produced
mean incidence rates of 0.93 [0.85, 1.00], 0.80 [0.75, 0.86] and 0.65 [0.59, 0.71], respectively,
corresponding to declines of 7%, 20% and 35% relative to baseline. With the High ART and
PMTCT intervention, Option A produced a mean incidence rate of 0.35 [0.33, 0.37] (mean
decline of 65% relative to baseline), while Options B and B+ produced similar incidence rates
of 0.28 [0.24, 0.31] and 0.29 [0.25, 0.33] (mean declines of 72% and 71%), respectively.
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In KZN, at Current coverage, Options B and B+ produced mean incidence rates of 2.41
[2.16, 2.66] and 2.12 [1.93, 2.31], corresponding to relative declines of 4% and 16% from base-
line, respectively (Fig 2). At High PMTCT coverage, Options A, B, and B+ produced mean inci-
dence rates of 2.44 [2.28, 2.59], 2.21 [1.99, 2.42], and 2.05 [1.94, 2.15]–declines of 3%, 12% and
19% respectively. At High ART and PMTCT coverage, Options A, B, and B+ produced mean
incidence rates of 0.79 [0.70, 0.87], 0.60 [0.52, 0.68] and 0.63 [0.53, 0.72], corresponding to
mean declines of 69%, 76%, and 75%, respectively.
As coverage for Option B+ increased from 20% to 80% with ART coverage held at Current
levels, the proportion of all HIV-infected individuals who were virally suppressed increased
from 31% to 47% in SW Uganda, and from 31% to 38% in KZN (Fig 3). For the same coverage
Fig 2. Annual incidence rates averaged over ten simulations for the ten-year intervention period in Uganda (top row) and South Africa (bottom
row). Each graph shows all three PMTCT interventions; the first, second and third columns represent Current, High PMTCT and High ART and PMTCT
coverage respectively. The error bars show 95% confidence intervals. The table below shows the mean incidence rate in the tenth year of the intervention,
95% confidence intervals are in the parentheses.
doi:10.1371/journal.pone.0134271.g002
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levels, mean incidence in SW Uganda declined from 0.89 [0.85, 0.93] to 0.63 [0.59, 0.68] (mean
decline of 29%), and in KZN from 2.45 [2.28, 2.62] to 1.95 [1.79, 2.12] (mean decline of 20%).
Scenario Analyses
In SW Uganda with South African ASFRs, mean HIV incidence was 0.99 [0.90, 1.08] in the
tenth year under Option A at Current coverage, and 0.83 [0.73, 0.92] under Option B+ at High
PMTCT coverage, a decline of 16%. In KZN with Ugandan ASFRs, mean incidence was 2.25
[2.06, 2.45] with Option A at Current coverage, and declined by 27% to 1.64 [1.45, 1.83] under
Option B+ at High PMTCT coverage.
In SW Uganda, under revised ART eligibility criterion of CD4500 cells/μl, mean HIV inci-
dence rates were 0.86 [0.77, 0.94] under Option A at Current coverage, and 0.63 [0.56, 0.69]
under Option B+ at High PMTCT coverage, corresponding to a 27% decline. In KZN, under
the revised criterion, mean incidence rates were 2.04 [1.89, 2.19] and 1.66 [1.51, 1.81] under
the two interventions, respectively, corresponding to a 19% decline.
Discussion
In addition to improving the health of mothers and reducing infant HIV infections, expanded
coverage of PMTCT has the potential to reduce population-level adult HIV incidence in both
high and low fertility settings in sub-Saharan Africa. At current levels of ART and PMTCT cov-
erage, changing from Option A to Options B or B+ could reduce HIV incidence by similar per-
centages in SW Uganda and KZN (approximately 5% and 15% for Option B and Option B+,
Fig 3. Mean HIV incidence rate in tenth year of Option B+ with High PMTCT coverage set at 20%, 40%,
60% and 80%. ART coverage is held constant at Current levels. On the right axis, we see the mean
proportion of virally suppressed individuals (viral load < 100 counts/ml), at the end of the tenth year of
intervention.
doi:10.1371/journal.pone.0134271.g003
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respectively). In models with increased PMTCT coverage at maintained ART coverage (High
PMTCT, Current ART model), Option B+ had a substantial impact in Uganda, reducing HIV
incidence by 35%, while Option B reduced incidence by 20%. In KZN, where both HIV preva-
lence and PMTCT coverage are high, the incidence reductions attributable to Options B and B
+ were not substantially changed by improving PMTCT coverage. As expected, the largest
declines in incidence in both countries were associated with higher overall ART coverage in
treatment programs among adults (High PMTCT, High ART model). In this scenario, the
incremental benefit of both Options B and B+ were reduced. Our conclusions are consistent
with prior modeling work on the population-level benefits of early ART initiation for HIV pre-
vention [52–55].
Our secondary analyses suggest that the variation in the findings between the two regions is
attributable to the proportion virally suppressed and to fertility rates. We found a direct rela-
tionship between Option B+ coverage, the proportion of virally suppressed HIV-infected indi-
viduals, and reduction in HIV incidence. However, as Option B+ coverage increased, there was
a greater increase in the proportion of HIV-infected individuals achieving viral suppression in
SW Uganda than KZN, likely because the higher fertility rates in SW Uganda allowed PMTCT
interventions to cover more women, and/or provide coverage for a longer period. Option B
+ had a reduced impact on population HIV incidence in SW Uganda when ASFRs were low-
ered to South African levels, and an increased impact in KZN when ASFRs were raised to
Ugandan levels. The higher mean fertility rates are correlated with a) a greater proportion of of
women who are pregnant and b) a lower age at first pregnancy. Both these factors increasing
the coverage of Option B+, and thus magnify its effect.
With ART eligibility at CD4500 cells/μl the incremental benefits of PMTCT interventions
were reduced in SW Uganda. In KZN, at all coverage levels, Options B and B+ had the same
impact on adult HIV incidence under the new ART eligibility criteria as under the original cri-
teria of CD4350 cells/μl. In Uganda, a moderate HIV prevalence country, higher CD4 at initi-
ation of ART may offset the added benefit of PMTCT. In a high prevalence setting such as
South Africa, however, the benefit of PMTCT is retained with expanded ART coverage. Note
that if ART is initiated at CD4500 cells/μl, Option B+ still has a greater relative impact on
HIV incidence in Uganda than in South Africa.
This study has several important limitations. Self-reported partnership data had to be
adjusted to balance the partnership numbers reported by men and women, and social desirabil-
ity may have limited reporting of multiple partners. We only modeled long-term partnerships
and did not consider casual sexual contacts because of the available data. Not including sub-
populations such as commercial sex workers may have led to an overestimation of the preven-
tion potential of PMTCT. We also assumed that all partnerships were homogeneous and
equally likely to dissolve; future empirical and modeling work may consider the typologies of
these partnerships, and their dissolution rates. Some model parameters were based on older
data; updated parameters could influence model conclusions. The model did not reflect the
dependencies between unprotected sex and risk of pregnancy. However, it did capture
increased risks of HIV acquisition and transmission during pregnancy. In addition, we did not
take into account certain factors that could affect HIV transmission and ART effectiveness,
such as migration and mobility patterns of individuals [56], dry sex [57], HIV subtypes [58],
and drug resistance [59].
The model did not consider the process of hemodilution [49], in which CD4 counts in HIV-
infected pregnant women are lower than in HIV-infected, non-pregnant women, after adjust-
ing for time of infection. Pregnant women may thus become eligible for ART sooner, and the
incidence reduction associated with PMTCT may be overestimated here. Also, a high propor-
tion of individuals on ART achieved viral suppression according to our empirical data; the
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impact of Option B+ on HIV incidence might be lower in other settings. We computed ART
coverage as a product of uptake and adherence, equivalent to assuming that individuals who
do not adhere to treatment never initiate ART. In reality, partial treatments may have some
population-level effects, which implies that the effects of interventions in our study may be
underestimated. Conversely, although our parameterization of PMTCT adherence does com-
bine estimates for antepartum and postpartum adherence, we did not model the two periods
separately, or account for changes in adherence after cessation of breastfeeding for women on
Option B+. Since recent studies report low adherence among women in this group, we may
overestimate the true impact of Option B+ [60,61]. Finally, we did not account for program
costs, or conduct a full cost-effectiveness analysis. As policymakers assess which strategies are
most efficient, an explicit consideration of costs is essential. We hope that our models (which
are publicly available) will provide the groundwork for future work in accounting for costs.
When choosing between PMTCT regimens and selecting coverage targets, policy-makers
will take into account estimates from many empirical studies and mathematical models on the
efficacy and cost-effectiveness of different regimens for preventing vertical transmission. Yet in
addition to those considerations, there are biological and epidemiological reasons for strength-
ening PMTCT programs beyond the benefits to the mother and her infant: pregnant women
are at increased risk of acquiring and transmitting HIV, and high coverage of antenatal care
provides good opportunities to link them to ART. Due to resource constraints, countries may
have to choose between implementing Option B+ or expanding coverage under Option B, and
our model results may help inform those decisions. The size of the effect of each regimen
depends on PMTCT coverage, fertility rates, and coverage of ART for treatment. The difference
between Options B and B+ is minimal when ART coverage is high, and is more pronounced at
lower coverage. Overall, increasing Option B coverage or implementing Option B+ at current
coverage both have potential to reduce HIV incidence, especially in Uganda, where fertility is
high and PMTCT coverage can be improved. In South Africa, larger reductions may be
achieved by expanding ART coverage to all HIV-infected persons instead of implementing
Option B+.
By considering our findings on the impact of PMTCT regimens on heterosexual transmis-
sion, in addition to evidence on vertical transmission, policy makers can thus derive more real-
istic estimates of each regimen’s impact on overall HIV incidence. We hope that this work will
provide motivation to policymakers to consider PMTCT as not just a strategy to reduce new
infections in infants, but also as a strategy to reduce adult HIV incidence.
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